share_log

Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Raises Price Target to $87

Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Raises Price Target to $87

Canaccord Genuity维持对Arcturus Therapeutics的买入,将目标股价上调至87美元
Moomoo 24/7 ·  03/11 07:51

Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and raises the price target from $81 to $87.

Canaccord Genuity分析师惠特尼·伊杰姆维持Arcturus Therapeutics(纳斯达克股票代码:ARCT)的买入并将目标股价从81美元上调至87美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发